An interventional study of Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland) and Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland) in Peripheral Artery Disease and Femoropopliteal Artery Disease, sponsored by Balton Sp.zo.o.. Completed at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-07.
Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.
Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is the 20th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2014, is one of 16 with no phase, and was the 9th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Poland, United States, Argentina and 15 more countries
Ages 18+
Wroclaw Medical University · Sites in Poland
Ages 18+
MDCECRO LLC · Sites in Poland
Ages 18–80
Balton Sp.zo.o. · Sites in Poland, Spain
Ages 18+
CSL Behring · Sites in Poland, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 11 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 220 across the 28 interventional studies, 300 across the 3 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 31 have an industry lead sponsor. The 10 most frequent:
Balton Sp.zo.o. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Balton Sp.zo.o. has 3 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07157475Wroclaw Medical UniversityVascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors | 2026-12-31 |
| NCT07122167MDCECRO LLCPost-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions | 2026-12-31 |
| NCT04349657KANDO ResearchA Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy | 2027-05 |
| NCT07049120Zhejiang Zylox Medical Device Co., Ltd.Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Peripheral Arterial Disease with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.
Although clinically effective, the manufacturing process of first generation PCB coatings contributed to inconsistent drug concentrations, particulate formations on the balloon surface and their shedding during the interventional procedures. As a consequence developments of new PCB coatings have been proposed to address consistency, uniformity, small particle drug coverage, which may potentially contribute to improved vessel healing profile and improved clinical outcomes. Nevertheless, data on the safety and efficacy of this novel coating developments in the clinical setting remain limited. Previously in the experimental model, the investigators reported that delivery of paclitaxel via a novel mcPCB resulted in low long-term tissue retention of paclitaxel, however displayed reduced neointimal proliferation and favorable healing profile. Therefore in current clinical trial the investigators will address the feasibility and safety of the mcPCB (PAK, Balton) in the treatment of femoropopliteal restenotic disease in a prospective, randomized manner when compared to plain balloon angioplasty (PBA). The efficacy analysis will be observational and evaluated post-hoc, with no prespecified criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plain Balloon Angioplasty
Device: Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)
plain balloon angioplasty followed by mcPCB dilation
Drug: Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)
Angiographic late lumen loss
Time frame: 6 months
Safety - Device related adverse events
Time frame: 30 days, 6 months
Critical limb ischemia
Time frame: 30 days, 6 months
Device Success
Successful delivery and deployment of the first inserted study device (in overlapping setting a successful delivery and deployment of the first and second study device) at the intended target lesion and successful withdrawal of the study device with attainment of final residual stenosis of less than 30% of the target lesion by quantitative vessel angiography (QVA).
Time frame: at procedure
Target Lesion Revascularization
Time frame: 6, 12, 24 months
Target vessel revascularization
Time frame: 6, 12, 24 months
Primary patency of treated segment
Time frame: 6, 12, 24 months
Treated limb amputation
Time frame: 30 days, 6 months
Change in ankle-brachial index
Time frame: pre-procedure, 3,6 and 12 months
Change in Walking Impairment Questionnaire (WIQ)
Time frame: pre procedure, 3, 6 and 12 months
Flow velocity in doppler ultrasonography
Time frame: 3, 6 and 12 months
The record gives a start of Sep 2014, a primary completion of Sep 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Balton Sp.zo.o.